Medical News

RSS

Breast tomosynthesis holds promise for early breast cancer detection

In the U.S., one out of eight women will develop breast cancer in her lifetime. The earlier the breast cancer is found, the more likely a woman will live a normal life, said Stephen Rose, M.D., a breast radiologist at Memorial Hermann Memorial City.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

$Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010$

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

Genmab A/S announced today that data from the pivotal trial of zalutumumab in refractory head and neck cancer patients will be presented today at the 2010 American Society of Clinical Oncology Annual Meeting, which will be held June 1-8 in Chicago, Illinois. This is the first controlled study to demonstrate that an EGFr-targeted antibody given as monotherapy induces a clinically meaningful improvement in progression free survival in patients with refractory head and neck cancer who have failed platinum-based chemotherapy.

9 Jun 2010

FDA should implement risk-based approach to tackle food safety problems: Report

The U.S. Food and Drug Administration's abilities to discover potential threats to food safety and prevent outbreaks of foodborne illness are hampered by impediments to efficient use of its limited resources and a piecemeal approach to gathering and using information on risks, says a new report by the Institute of Medicine and National Research Council.

9 Jun 2010

Allscripts, Eclipsys announce merger

Allscripts, the leading provider of clinical software, information and connectivity solutions for physicians, and Eclipsys, a leading enterprise provider of solutions and services for hospitals and clinicians, today announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.

9 Jun 2010

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Young girls who drink soda have less healthy diets through adolescence than their peers who do not drink soda, according to a Penn State study. The ten-year study showed that girls who drank soda at age five had diets that were less likely to meet nutritional standards for the duration of the study, which ended at age 15. Girls who did not drink soda at age five did not meet certain nutritional requirements, but their diets were healthier.

9 Jun 2010

4% of South Asian people carry mutated gene that causes heart failure

One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.

9 Jun 2010

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

BSD Medical Corporation today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology, which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

9 Jun 2010

Covance opens state-of-the-art biorepository facility at Greenfield

Covance Inc., a leading provider of drug development services, announced today that it has opened a state-of-the-art biorepository facility at its Greenfield, Indiana location. The 20,000-square-foot building is dedicated to long-term storage of clinical trial specimens. The facility is able to store a wide-range of specimens, including plasma, serum, whole blood, DNA, PBMC, and tissue.

9 Jun 2010

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Stem cell research holds promise for improving the quality of human life ― especially embryonic stem cells, which can potentially develop into any tissue in the human body. However, basic scientific problems still remain unresolved -- but Tel Aviv University researchers are leading the way to inventive solutions.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute researchers have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

9 Jun 2010

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.

9 Jun 2010

Better understanding of eye movements can help develop strategies for reducing crash risks: Study

More than 16 people are killed and more than 1,300 people are injured each day in crashes involving a distracted driver, a phenomenon that could be reduced with the right application of motion information and appropriate eye movements.

9 Jun 2010

Pharnext closes €4.8-million Series A funding round

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it had closed a €4.8-million Series A round of funding on June 3rd (corresponding to a company valuation of €45 million).

9 Jun 2010

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Short people are at greater risk of developing heart disease than tall people, according to the first systematic review and meta-analysis of all the available evidence, which is published online today (Wednesday 9 June) in the European Heart Journal.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

RoundTable signs agreement to acquire Ophthalmic Systems business unit

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the health-care industry, announced today that is has entered into an agreement with BD to acquire the Ophthalmic Systems unit, a business within the BD Medical segment. BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.

9 Jun 2010

Medical News

Breast tomosynthesis holds promise for early breast cancer detection

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

Pivotal trial data of zalutumumab in refractory head and neck cancer patients presented at ASCO 2010

FDA should implement risk-based approach to tackle food safety problems: Report

Allscripts, Eclipsys announce merger

Penn State study: Young girls who drink soda have less healthy diets through adolescence

4% of South Asian people carry mutated gene that causes heart failure

Blood vessel-blocking drug slows prostate cancer progression: Experts

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

Covance opens state-of-the-art biorepository facility at Greenfield

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

VARI researchers identify enzyme that could help diagnose and treat cholangiocarcinoma

Merck's MK-4305 improves overall sleep efficiency in primary insomnia patients

Better understanding of eye movements can help develop strategies for reducing crash risks: Study

Pharnext closes €4.8-million Series A funding round

Short people at greater risk of developing CVD or CHD compared to tall people: Review

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

RoundTable signs agreement to acquire Ophthalmic Systems business unit

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News